Loading patent…
OwnerJerome Celerier, Amauri Cruz +3inventors
InventorsJerome Celerier, Amauri Cruz, Noel Lamande, Jean-Marie Gasc, Pierre Corvol
Estimating the term…
An object of the present invention is the use of at least one inhibitor of angiogenesis consisting of AGT or derivatives thereof in the manufacture of a drug for treating pathologies or disorders notably angiogenesis-dependent or mediated pathologies generally characterised by excessive angiogenesis. The present invention also relates to a cell transfected with at least one expression vector wherein said expression vector hosts a recombinant nucleic acid encoding an AGT or one of its derivatives for use in therapy of angiogenesis-mediated pathologies. The present invention further relates to an expression vector for use in said cell.
Use of at least one molecule of angiotensinogen or derivatives thereof consisting of des(AngI)AGT or RCL-cleaved AGT in the manufacture of a drug for use in the treatment of anglogenesis-mediated or dependent pathologies.
Use of a compound comprising at least one recombinant nucleic acid encoding an AGT or one of its derivatives inserted within an expression vector wherein said expression results in production of an anti-anglogenic protein in the manufacture of a drug for treating angiogenesis-mediated or dependent pathologies.
Use according to anyone of the preceding claim, in combination with the use of an other compound selected in the group consisting of anti-angiogenic, anti-cancerous anti-mitotic comp pounds or agents
Dependencies are inferred from the claim text.